journal article·2021-04

Potential applications of armchair, zigzag, and chiral boron nitride nanotubes as a drug delivery system: Letrozole anticancer drug encapsulation

Hamed Sargazi-Avval, Mehdi Yoosefian, Mansour Ghaffari-Moghaddam, Mostafa Khajeh, Mousa Bohlooli

Applied Physics A· Volume 127· Issue 4
Publisher page

Abstract

A density functional theory calculation has been applied to be investigated the ability of (12,12) armchair, (21,0) zigzag, and (18,5) chiral boron nitride nanotubes (BNNT) as the drug nanocarrier in Letrozole delivery. For this purpose, the behavior of drug Letrozole when encapsulated into different chirality of BNNTs with the same diameter was studied. Moreover, the reduced side effects and increasing solubility of Letrozole can be achieved by encapsulation in boron nitride nanotubes. A complete understanding of the encapsulation process of drug molecules into BNNTs is necessary for the development of drug delivery systems. Geometry optimizations of the three types of BNNTs and drug Letrozole have been performed by means of density functional theory calculation, using the functional wb97xd with 6-31G basis set. The results indicate that Letrozole is encapsulated in cavity of the nanotubes. The structural and the electronic properties of encapsulated Letrozole in the studied systems have been also predicted by quantum mechanical descriptors such as equilibrium distances, highest occupied molecular orbital (HOMO)—lowest unoccupied molecular orbital (LUMO) energy gap. The quantum mechanical calculations verify that the armchair and the chiral single-walled boron nitride nanotubes could spontaneously adsorb Letrozole in a chemisorption process while the physisorption process plays a large role in adsorption within the zigzag single-walled boron nitride nanotube.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Boron and Carbon Nanomaterials Research · Graphene research and applications · Fullerene Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. J.N. Ingle, P.A. Johnson, V.J. Suman, J.B. Gerstner, J.A. Mailliard, J.K. Camoriano, D.H. Gesme Jr., C.L. Loprinzi, A.K. Hatfield, L.C. Hartmann, A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer Interdiscip. Int. J. Am. Cancer Soc. 80, 218–224 (1997)
2. T. Iveson, I. Smith, J. Ahern, D. Smithers, P. Trunet, M. Dowsett, Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53, 266–270 (1993)
3. N.K. Ibrahim, A.U. Buzdar, Aromatase inhibitors: current status. Am. J. Clin. Oncol. 18, 407–417 (1995)10.1097/00000421-199510000-00010 ↗
4. H.J. Burstein, J.J. Griggs, A.A. Prestrud, S. Temin, American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J. Oncol. Pract. 6, 243–246 (2010)10.1200/JOP.000082 ↗
5. K. Wasan, P. Goss, P.H. Pritchard, L. Shepherd, M. Palmer, S. Liu, D. Tu, J. Ingle, M. Heath, D. Deangelis, The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA. 17L). Ann. Oncol. 16, 707–715 (2005)10.1093/annonc/mdi158 ↗
6. E.A. Perez, R.G. Josse, K.I. Pritchard, J.N. Ingle, S. Martino, B.P. Findlay, T.N. Shenkier, R.G. Tozer, M.J. Palmer, L.E. Shepherd, Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA. 17. J. Clin. Oncol. 24, 3629–3635 (2006)10.1200/JCO.2005.05.4882 ↗
7. A. Monnier, Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review. Ther. Clin. Risk Manag. 5, 725 (2009)10.2147/TCRM.S3858 ↗
8. S. Senapati, A.K. Mahanta, S. Kumar, P. Maiti, Controlled drug delivery vehicles for cancer treatment and their performance. Signal Trans. Target. Ther. 3, 1–19 (2018)10.1038/s41392-017-0001-6 ↗
9. T.M. Allen, P.R. Cullis, Drug delivery systems: entering the mainstream. Science 303, 1818–1822 (2004)10.1126/science.1095833 ↗
10. M. Cao, D. Wu, M. Yoosefian, S. Sabaei, M. Jahani, Comprehensive study of the encapsulation of Lomustine anticancer drug into single walled carbon nanotubes (SWCNTs): Solvent effects, molecular conformations, electronic properties and intramolecular hydrogen bond strength. J. Mol. Liquids 320, 114285 (2020)10.1016/j.molliq.2020.114285 ↗
11. M. Yoosefian, E. Mirhaji, M. Afshar, A. Juan, Molecular dynamics simulations on interaction of ssDNA-causing DM1 with carbon and boron nitride nanotubes to inhibit the formation of CTG repeat secondary structures. Appl. Surf. Sci. 524, 146572 (2020)10.1016/j.apsusc.2020.146572 ↗
12. M. Yoosefian, N. Etminan, A. Juan, E. Mirhaji, Ultra-low concentration protein detection based on phenylalanine–Pd/SWCNT as a high sensitivity nanoreceptor. RSC Adv. 10, 2650–2660 (2020)10.1039/C9RA09243A ↗
13. M. Yoosefian, S. Sabaei, N. Etminan, Encapsulation efficiency of single-walled carbon nanotube for Ifosfamide anti-cancer drug. Comput. Biol. Med. 114, 103433 (2019)10.1016/j.compbiomed.2019.103433 ↗
14. M. Yoosefian, M. Jahani, A molecular study on drug delivery system based on carbon nanotube for the novel norepinephrine prodrug, Droxidopa. J. Mol. Liquids 284, 258 (2019)10.1016/j.molliq.2019.04.016 ↗
15. M. Yoosefian, E. Rahmanifar, N. Etminan, Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis. Artif. Cells Nanomed. Biotechnol. 46, 434–446 (2018)10.1080/21691401.2018.1430583 ↗
16. M. Terrones, J. Romo-Herrera, E. Cruz-Silva, F. Lopez-Urias, E. Munoz-Sandoval, J. Velázquez-Salazar, H. Terrones, Y. Bando, D. Golberg, Pure and doped boron nitride nanotubes. Mater. Today 10, 30–38 (2007)10.1016/S1369-7021(07)70077-9 ↗
17. E. Mirhaji, M. Afshar, S. Rezvani, M. Yoosefian, Boron nitride nanotubes as a nanotransporter for anti-cancer docetaxel drug in water/ethanol solution. J. Mol. Liq. 271, 151–156 (2018)10.1016/j.molliq.2018.08.142 ↗
18. M. El Khalifi, E. Duverger, T. Gharbi, H. Boulahdour, F. Picaud, Theoretical use of boron nitride nanotubes as a perfect container for anticancer molecules. Anal. Methods 8, 1367–1372 (2016)10.1039/C5AY02822A ↗
19. G. Ciofani, Potential applications of boron nitride nanotubes as drug delivery systems. Expert Opin. Drug Deliv. 7, 889–893 (2010)10.1517/17425247.2010.499897 ↗
20. G. Ciofani, V. Raffa, J. Yu, Y. Chen, Y. Obata, S. Takeoka, A. Menciassi, A. Cuschieri, Boron nitride nanotubes: a novel vector for targeted magnetic drug delivery. Curr. Nanosci. 5, 33–38 (2009)10.2174/157341309787314557 ↗
21. S. Ghahremani, M. Samadizadeh, M. Khaleghian, N. Zabarjad Shiraz, Theoretical study of encapsulation of Floxuridine anticancer drug into BN (9, 9–7) nanotube for medical application. Phosphorus Sulfur Silicon Relat. Elem. 195, 293–306 (2020)10.1080/10426507.2019.1687479 ↗
22. L.-Y. Feng, Y.-J. Liu, J.-X. Zhao, Y.-H. Ding, Theoretical study on the encapsulation of Li atoms inside boron nitride nanotubes: physical properties and catalytic reactivity for the oxygen reduction reaction. J. Phys. Chem. C 118, 30325–30332 (2014)10.1021/jp5109043 ↗
23. G. Ciofani, S. Danti, D. D’Alessandro, S. Moscato, A. Menciassi, Assessing cytotoxicity of boron nitride nanotubes: interference with the MTT assay. Biochem. Biophys. Res. Commun. 394, 405–411 (2010)10.1016/j.bbrc.2010.03.035 ↗
24. G. Ciofani, V. Raffa, A. Menciassi, A. Cuschieri, Boron nitride nanotubes: an innovative tool for nanomedicine. Nano Today 4, 8–10 (2009)10.1016/j.nantod.2008.09.001 ↗
25. M. Frisch, G. Trucks, H. Schlegel, G. Scuseria, M. Robb, J. Cheeseman, J. Montgomery Jr., T. Vreven, K. Kudin, J. Burant, Gaussian 03 (Gaussian Inc, Wallingford, CT, 2004).
26. P.J. Hay, W.R. Wadt, Ab initio effective core potentials for molecular calculations Potentials for K to Au including the outermost core orbitals. J. Chem. Phys. 82, 299–310 (1985)10.1063/1.448975 ↗
27. A.D. Becke, Density-functional thermochemistry: III—the role of exact exchange. J. Chem. Phys. 98, 5648–5652 (1993)10.1063/1.464913 ↗
28. T. Koopmans, Über die Zuordnung von Wellenfunktionen und Eigenwerten zu den einzelnen Elektronen eines Atoms. Physica 1, 104–113 (1934)10.1016/S0031-8914(34)90011-2 ↗
29. R.G. Parr, L.V. Szentpaly, S. Liu, Electrophilicity index. J. Am. Chem. Soc. 121, 1922–1924 (1999)10.1021/ja983494x ↗
30. K. Fukui, Role of frontier orbitals in chemical reactions. Science 218, 747–754 (1982)10.1126/science.218.4574.747 ↗